Abstracts Archive - Page 1210 of 2607 - ACR Meeting Abstracts

Abstract Number: 353 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
José Luis Martín-Varillas¹, Íñigo González-Mazón¹, Belén Atienza-Mateo¹, Marina Delagado Ruiz², Isabel Bernat Piña², Diana Prieto Peña³, Monica Calderón Goercke³, Lara Sánchez-Bilbao¹, Eva Peña Sainz-Pardo², Almudena García Castaño², Miguel Angel González-Gay² and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Immune checkpoint blockade therapy (ICTB) has shown remarkable benefit in different cancer types. Blockade of intrinsic down-regulators of immunity increases the activity of the…
Abstract Number: 354 • 2018 ACR/ARHP Annual Meeting
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Mazen Nasrallah¹, Meghan Mooradian², Eli Miloslavsky³, Justine Cohen², Justin Gainor², Donald Lawrence², Kerry Reynolds², Minna Kohler⁴, Ryan Sullivan² and Sara Schoenfeld¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have led to improved outcomes in multiple cancers, but they are associated with immune-related adverse events (irAEs), including inflammatory arthritis.…
Abstract Number: 355 • 2018 ACR/ARHP Annual Meeting
Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Laura C. Cappelli¹, Mehmet Tevfik Dorak², Clifton O. Bingham III³ and Ami A. Shah¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Kingston University London, Kingston upon Thames, United Kingdom, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI), an important type of cancer therapy, can cause adverse events through immune activation. Inflammatory arthritis (IA) due to ICI treatment…
Abstract Number: 356 • 2018 ACR/ARHP Annual Meeting
Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
Rachel Romero¹, Todd Schwartz², Shruti Saxena Beem¹ and Rumey Ishizawar³, ¹Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICI) targeting CTLA-4, such as ipilimumab (anti-CTLA4), or PD-1/PD-L1, such as nivolumab and pembrolizumab are increasingly utilized in a wide variety…
Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Abhishikta Dey^1,2, Nicholas Manolios^3,4, Georgina Long^4,5,6, Richard Kefford^3,4,5,7 and Leslie Schrieber^8,9, ¹Pain Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, ²Royal North Shore Hospital, North Sydney, Australia, ³Westmead Hospital, Sydney, Australia, ⁴University of Sydney, Sydney, Australia, ⁵Melanoma Institute Australia, North Sydney, Australia, ⁶Royal North Shore Hospital, St Leonards, Australia, ⁷Macquarie University Hospital, Sydney, Australia, ⁸Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁹Northern Clinical School, University of Sydney, Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…
Abstract Number: 358 • 2018 ACR/ARHP Annual Meeting
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
Sang Kim¹, Vickie Shannon², Ajay Sheshardi², Hagop Kantarjian³, Guillermo Garcia-Manero³, Farhad Ravandi³, Aung Naing⁴, Padmanee Sharma⁵, Jin Im⁶, Wilfredo Ruiz Vazquez⁶, Adi Diab⁷, Dimitrios Kontoyiannis⁸, Andrew Futreal⁹ and Naval Daver³, ¹General Internal Medicine, MD Anderson Cancer Center, Houston, TX, ²Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, ³Leukemia, MD Anderson Cancer Center, Houston, TX, ⁴Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, ⁵Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁶Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, ⁷Melanoma Medical Oncology, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁸Infectious Diseases, MD Anderson Cancer Center, Houston, TX, ⁹Genomic Medicine, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitor (ICI)-based combinations are showing encouraging results in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment; however, ICIs can cause immune-related…
Abstract Number: 359 • 2018 ACR/ARHP Annual Meeting
Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis
Sang Kim¹, Jean Tayar¹, Huifang Lu¹, Jennifer Wang², Don Gibbons³, Guillermo Garcia-Manero⁴, Patrick Hwu⁵, Adi Diab⁵ and Roza Nurieva⁶, ¹General Internal Medicine (Rheumatology), MD Anderson Cancer Center, Houston, TX, ²Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, ³Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁴Leukemia, MD Anderson Cancer Center, Houston, TX, ⁵Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁶Immunology, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Checkpoint inhibitors (ICIs) are revolutionizing cancer treatment; however, ICI therapy is associated with immune-related adverse events (irAEs). irAEs can be life-threatening and/or severely impair…
Abstract Number: 360 • 2018 ACR/ARHP Annual Meeting
Sarcoidosis Induced By Immune Check Point Inhibitors
Noémie Chanson¹, Pauline Pradère², Anne-Laure Voisin³, Stéphane Champiat⁴, Aurélien Marabelle⁴ and Olivier Lambotte⁵, ¹Internal Medicine, Hopital Bicetre, LE KREMLIN BICETRE, France, ²Hopital Marie Lannelongue, Le Plessis Robinson, France, ³Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, ⁴Drug Development Department, Gustave Roussy Institut, Villejuif, France, ⁵Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France
Background/Purpose: Immune check point inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have demonstrated improved survival for multiple cancers…
Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
In Young Kim¹, Yeonghee Eun¹, Hyungjin Kim¹, Joong Kyong Ahn², Eun-Jung Park³, Chan Hong Jeon⁴, Jinseok Kim⁵, Hoon-Suk Cha¹, Eun-Mi Koh¹ and Jaejoon Lee¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ³Department of Medicine, National Medical Center, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…
Abstract Number: 362 • 2018 ACR/ARHP Annual Meeting
Immune Check Point Inhibitors, Auto-Antibodies, and Immune Adverse Reactions
Aradhna Agarwal¹, Alexa Meara² and Dight Owen³, ¹The Ohio State University Collge of Medicine, Columbus, OK, ²Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Oncology, The Ohio State Univeristy Wexner Medical Center, Columbus, OH
Background/Purpose: Immune checkpoint inhibitors (ICI) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) and its ligand PD-L1 have had substantial…
Abstract Number: 363 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?
Valeria Scaglioni¹, Marina Scolnik¹, Jose Maria Lastiri², Lorena Lupinacci² and Enrique R Soriano¹, ¹Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ²Oncology Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Over the years there has been a huge effort to change the traditional way to treat cancer, that was previously based on chemotherapy and/or…
Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Nicholas Meti¹, Khashayar Esfahani^1,2, Ines Colmegna^1,3, Marvin J. Fritzler⁴, Nathalie A. Johnson^1,5, Ciriaco Piccirillo^1,6, Wilson H. Miller Jr.^1,2 and Marie Hudson^1,7, ¹Department of Medicine, McGill University, Montreal, QC, Canada, ²Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, ³Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, ⁶Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
Abstract Number: 365 • 2018 ACR/ARHP Annual Meeting
Monoclonal Gammopathy in Rheumatic Diseases
Yue Yang, Yuan Jia, Shi Chen, Yin Su and Zhan-Guo Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: To analyze the clinical spectrum, laboratory characteristics, and outcomes of monoclonal gammopathy (MG) in patients with rheumatic diseases. Methods: Screening for the presence of…
Abstract Number: 366 • 2018 ACR/ARHP Annual Meeting
Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
Fatima Alduraibi¹, Monica Lawrence², Larry Borish² and Adam Carlson³, ¹Department of Medicine, University of Virginia Health System, charlottesville, VA, ²Department of Medicine, Division of Allergy and Immunology, University of Virginia Health System, Charlottesville, VA, ³Department of Medicine, Division of Rheumatology, University of Virginia Health System, Charlottesville, VA
Background/Purpose: Common variable immunodeficiency (CVID) is one of the most common symptomatic primary immunodeficiency syndrome with an incidence of ~1 in 25,000 people. CVID is…
Abstract Number: 367 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
Bruno Emond¹, Lorie A. Ellis², Soumya D Chakravarty³, Martin Ladouceur¹ and Patrick Lefebvre¹, ¹Analysis Group, Inc., Montréal, QC, Canada, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA
Background/Purpose: IBD is often associated with other CID, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Newer biologic agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].